Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826021755?dgcid=rss_sd_all
Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826021755?dgcid=rss_sd_all
“Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer.” European Urology.
@article{article116727,
title = {Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826021755?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...